Arch Therapeutics Co-Founder Rutledge Ellis-Behnke, PhD Presents at Two Scientific Meetings in March
27 March 2014 - 12:00AM
Marketwired
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke, PhD Presents at
Two Scientific Meetings in March
Discusses AC5(TM) at the Brainstorming Neuromodulation Workshop
and 4th Annual Meeting of American Society of Nanomedicine
WELLESLEY, MA--(Marketwired - Mar 26, 2014) - Rutledge
Ellis-Behnke, PhD, co-founder and inventing scientist at Arch
Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or "the Company"), a life
sciences company and developer of the AC5 Surgical Hemostatic
Device™, a novel product aimed at controlling bleeding and fluid
loss in order to provide faster and safer surgical and
interventional care, presents his work using AC5™ at two scientific
meetings.
At the upcoming 4th Annual Meeting of the American Society for
Nanomedicine in Rockville, Maryland on March 28-30, Dr.
Ellis-Behnke will present his hemostasis and tissue stabilization
work using self-assembling compositions, including AC5 and other
compositions that have been licensed to Arch. Dr. Ellis-Behnke will
present on Saturday, March 30 at 9:25 AM EST in a talk titled "New
Molecular Medical Devices: A Framework, Objective Measures and
Treatments That Can Help Restore the Body to a Pre-injury
State."
Information about the American Society for Nanomedicine may be
found on their website at the following link
http://amsocnanomed.org.
Dr. Ellis-Behnke noted, "The use of AC5 to control bleeding
during surgery also stabilizes the tissue, which increases the
stability of any implantable device. By quickly stopping bleeding,
there is little or no edema and the leads will stay where they are
placed. Revisions can be greatly reduced. Additionally, through the
stabilization of tissue and hemostatic activity, the severity of
the damage from trauma and disease can be significantly mitigated,
thus reducing recovery time and the risk of developing secondary
damage or infection."
He continued, "Arch Therapeutics' work is of vital importance in
this field as it is instrumental in understanding how to translate
these discoveries into commercially viable processes and products
designed to fulfill areas of extraordinary medical need."
Also, at the recent "Brainstorming Neuromodulation" workshop in
Carmel, California held on March 14-16, Dr. Ellis-Behnke showed how
AC5 stops bleeding during brain surgery. This biannual,
invitation-only workshop was organized by Bay Area neurologist
Russell Andrews, MD, Medical Advisor for Neurosurgery at NASA Ames
Research Center and President of the International Conference on
Neuroprotective Agents.
Terrence W. Norchi, M.D., Chief Executive Officer of Arch
Therapeutics, said, "We continue to be grateful to Dr. Ellis-Behnke
for his work on behalf of the Company, both in terms of his
scientific contributions to the development of AC5 and his ongoing
outreach to the scientific community to convey AC5's unique
benefits."
About Arch Therapeutics, Inc. Arch Therapeutics, Inc. is a
medical device company developing a novel approach to stop bleeding
(hemostasis) and control leaking (sealant) during surgery and
trauma care. Arch is developing products based on an innovative
self-assembling peptide technology platform to make surgery and
interventional care faster and safer for patients. Arch's flagship
development stage product candidate, known as AC5™, is being
designed to achieve hemostasis in minimally invasive and open
surgical procedures.
Find out more at www.archtherapeutics.com.
Notice Regarding Forward-Looking Statements This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the Securities Act of 1933, as amended, and
Section 21(e) of the Securities Exchange Act of 1934, as amended.
Statements in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future.
Such forward-looking statements include, among other things,
references to novel technologies and methods, our business and
product development plans and projections, or market information.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the inherent uncertainties associated with
developing new products or technologies and operating as a
development stage company, our ability to retain important members
of our management team and attract other qualified personnel, our
ability to raise the additional funding we will need to continue to
pursue our business and product development plans, our ability to
develop and commercialize products based on our technology
platform, and market conditions. These forward-looking statements
are made as of the date of this news release, and we assume no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements. Although we believe that any
beliefs, plans, expectations and intentions contained in this press
release are reasonable, there can be no assurance that any such
beliefs, plans, expectations or intentions will prove to be
accurate. Investors should consult all of the information set forth
herein and should also refer to the risk factors disclosure
outlined in the reports and other documents we file with the SEC,
available at www.sec.gov.
On Behalf of the Board, Terrence W. Norchi, MD Arch
Therapeutics, Inc.
Contact: ARTH Investor Relations Toll Free: +1-855-340-ARTH
(2784) (US and Canada) Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Sep 2023 to Sep 2024